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Pancreatic Cystic Neoplasms: Introduction and 
Background
There is a plethora of cystic lesions in the pancreas, ranging 
from the most common finding of pancreatic pseudocysts to rare 
abnormities such as congenital cysts, as well as various cystic neo-
plasms [1–3]. Whilst some cystic neoplasms, such as serous cystic 
neoplasms (SCN), can generally be considered of benign origin, 
others, like mucinous cystic neoplasms (MCN) or intraductal pap-
illary mucinous neoplasms (IPMNs), harbor a significant malig-
nant potential [1]. An overview of cystic lesions and their fre-
quency can be found in table  1. The radiological distinction be-
tween malignant, premalignant, and benign lesions as well as the 
classification of non-neoplastic cystic pancreatic masses such as 
congenital cysts and pseudocysts can be complex [1–3]. However, 
the exclusion of malignancy in any pancreatic lesion is essential. 
This may involve imaging, endosonography-guided fine needle as-
piration (FNA) to obtain cytology and biochemical markers of mu-
cinous, serous, or inflammatory cystic lesions and surgical resec-
tion, followed by histopathological evaluation [4]. 
Regarding potentially malignant cystic pancreatic neoplasms 
that are lined by a mucinous epithelium, several discriminating 
 criteria evolved during the past years, not least due to improved 
radiological techniques and thorough pathological workup [4]. 
Thus, MCN, which histologically contain an ovarian-like stroma in 
general, typically do not involve pancreatic ducts, while IPMNs 
were shown to arise from the pancreatic ductal system [1, 5, 6]. As 
subsequently described in detail, IPMNs are regarded as premalig-
nant lesions going through a cascade of malignant transformation, 
starting as IPMN with low-grade dysplasia (also termed adenomas) 
and possibly progressing into IPMNs with associated invasive 
carcinoma. 
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Summary
Background: Intraductal papillary mucinous neoplasms 
(IPMNs) display diverse macroscopic, histological, and 
immunohistochemical characteristics with typical mor-
phological appearance in magnetic resonance imaging. 
Depending on those, IPMNs may show progression into 
invasive carcinomas with variable frequency. Overall, 
IPMN-associated invasive carcinomas are found in about 
30% of all IPMNs, revealing phenotpyes comparable 
with conventional ductal adenocarcinomas or mucinous 
(colloid) carcinomas of the pancreas. In Sendai-negative 
side-branch IPMNs, however, the annual risk of the de-
velopment of invasive cancer is 2%; thus, risk stratifica-
tion with regard to imaging and preoperative biomarkers 
and cytology is mandatory. Methods and Results: The 
present study addresses the radiological and interven-
tional preoperative measures including histological fea-
tures to determine the risk of malignancy and the prog-
nosis of IPMNs. Conclusion: While preoperative imaging 
largely relies on the detection of macroscopic features of 
IPMNs, which are associated with a divergent risk of ma-
lignant behavior, in resected specimens the determina-
tion of the grade of dysplasia and the detection of an in-
vasive component are the most important features to 
estimate the prognosis of IPMNs.
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IPMNs are cystic lesions of the pancreas that are derived from 
the pancreatic ducts [3, 4, 7]. They can affect the main pancreatic 
duct (MPD), the branch ducts (BD), or both. IPMNs arising from 
the MPD are called MD-IPMNs, lesions arising from the BDs are 
called BD-IPMNs, and lesions involving both the MPD as well as 
the BDs are called mixed-type IPMNs [8]. The majority of IPMNs 
are found in the head but they can also be found in the body, tail, 
or throughout the pancreas, with the majority of the lesions being 
of the BD-IPMN subtype [6]. 
Epidemiology and Etiology
The incidence of IPMNs in the population is difficult to assess 
due to the increasing awareness of them as well as the increasing 
quality of imaging modalities. However, studies currently predict 
an incidence of 2 cases per 100,000. Imaging of the pancreas shows 
cystic lesions in 2.5% of asymptomatic patients and in 10% if a 
population older than 80 years is screened [9, 10]. The median size 
of cystic lesions is 8 mm, and in up to 30% multifocal cystic lesions 
are found [11]. Autopsy studies reveal side-branch IPMN (BD-
IPMN) in 20% of the patients without significant dysplasia [12]. 
IPMNs mostly occur at an older age (mean age 64–67 years), with a 
slightly higher risk in men according to the literature [2, 13]. While 
95.8% of all MD-IPMNs present either as high-grade dysplasia 
or invasive cancer, the rate of malignancy in BD-IPMNs is much 
lower, which poses the necessity for risk stratification. The risk of 
malignancy development in BD-IPMN is estimated with 2% per 
year [11].
The etiology of IPMNs is largely unknown. Nevertheless, some 
genetic factors could be associated with the genesis of IPMNs, and 
although occurring sporadically in most cases, some IPMNs were 
found to arise within hereditary syndromes [13–18]. The latter in-
cluded familial adenomatous polyposis (FAP), an inherited disease 
that mainly affects the colon and rectum – classically due to muta-
tions in the APC gene, which codes for the adenomatous polyposis 
coli (APC) protein [13, 14]. It is the loss of function of this gene 
that results in pathology. Various case studies have shown that in 
those patients with FAP and IPMN there is almost an identical im-
munohistochemical staining, with those lesions found in FAP and 
the IPMNs showing loss of the APC protein [19]. Another inher-
ited gastrointestinal tumor syndrome is Lynch syndrome, also 
known as hereditary nonpolyposis colorectal carcinoma (HNPCC) 
[17]. HNPCC is associated with microsatellite instability (MSI) and 
lack of MSH2 and MSH6 expression (depending on HNPCC type). 
Studies have revealed that IPMNs are more often associated with 
other nonpancreatic cancer manifestations and are sometimes as-
sociated with MSI, MSH2, or MSH6 [17, 18] as well as BRCA2 mu-
tations, which were found in 25% of IPMN patients with a family 
history of pancreatic cancer in a study by Lubezky et al. [17]. As-
sociations with Peutz-Jeghers syndrome have also been described 
in the literature [5]. Furthermore, studies examining the rate of ex-
trapancreatic neoplasms have shown that patients with an IPMN 
have an increased rate of extrapancreatic neoplasms in 3.5–9.3% 
depending on the follow-up time, the most frequent being colonic, 
gastric, prostatic, and breast carcinomas [2, 4, 5, 16, 17, 20]. In a 
number of patients with McCune-Albright syndrome, character-
ized by fibrous dysplasia, precocious puberty, and café au lait spots, 
IPMNs have been described as a McCune-Albright syndrome-as-
sociated tumor, present in about 15% of the patients. In these pa-
tients, germline GNAS-activating mutations are reported which 
lead to IPMNs, underlining the concept of somatic GNAS muta-
tions being diagnostic in IPMN [20, 21].
Pathological Features
Generally, IPMNs may display a dilatation of ducts or have a 
multicystic appearance, especially if they arise from BDs (WHO 
2010). Within the cysts, papillary structures may be found [2, 7, 
21]. Furthermore, IPMNs are typically filled with mucin of viscous 
consistency [2, 4, 22]. In some cases, mucous secretion into the 
duodenum can be seen [23–25]. The size of the cystic ducts ranges 
from 10 to 80 mm in diameter (WHO 2010). Due to intraductal 
obstruction caused by the tumors, the remaining pancreatic paren-
chyma may display a marked atrophy [22].
IPMNs can arise in the entire pancreas but most frequently af-
fect the pancreatic head [6]. In a significant subset of IPMNs, mul-
ticentricity has been described [26]. Based on their ductal involve-
ment, as also mirrored in radiological investigations, IPMNs may 
macroscopically be subclassified into MD-type, BD-type, or mixed-
type IPMNs [6, 8]. While this classification is important for preop-
erative risk assessment, as obtained by radiographic imaging, it has 
Table 1. Frequency of cystic lesions of the pancreas of resected cases [54]
Cystic lesion Frequency
Overall frequency (autopsy cases) 24.3% (73/300)
Serous cystadenoma (SCN)    10%
Mucinous cystadenoma (MCN)     8%
Solid pseudopapillary neoplasm    10%
IPMN    24%
Ductal adenocarcinoma with cystic features    21%
Pancreatic pseudocyst    34%
MUC1 MUC2 MUC5AC MUC6 CDX2
Pancreatobiliary + – + rarely + –
Intestinal – + + (+) +
Gastric – – + + –
Oncocytic + goblet cells goblet cells + –
Table 2. Subtyping of IPMN (according to [6, 8])
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been suggested to be of minor importance for the pathological 
workup, since microscopically most tumors show involvement of 
both MD and BD [8].
These different types may display slightly different morphologic 
features. Thus, MD-IPMNs are more likely to contain intramural 
nodules or present as a mass lesion in a dilated duct [2, 3]. They are 
more frequent in the pancreatic head but may affect the entire pan-
creatic main duct, eventually progressing into the branches [22]. 
BD-IPMNs can have a multicystic appearance and usually do not 
show intracystic papillary features macroscopically [2, 27].
A B
C D
Fig. 1. Various histological types of IPMNs. A Pancreatobiliary type, B intes-
tinal type, C gastric type, and D oncocytic type.
D
A CB
E
Fig. 2. Histological findings in noninvasive (A–C) 
and invasive (D, E) IPMNs, revealing low-grade 
dysplasia (A), intermediate-grade dysplasia (B), and 
high-grade dysplasia (C), as well as invasive growth 
with the phenotypes of a ductal adenocarcinoma 
(D) and of a mucinous (colloid) carcinoma (E).
Histological Features
Overall, IPMNs consist of intraductal proliferations of mucin-
producing, columnar epithelial cells [6]. As summarized in table 2 
and figure 1, based on histological and immunohistochemical fea-
tures, IPMNs may be subclassified into pancreatobiliary-type, in-
testinal-type, gastric-type, and oncocytic-type IPMNs [6].
The intestinal subtype represents the most common subtype of 
the MD-IPMN. It is characterized by a villous growth pattern with 
tall columnar epithelial cells with elongated nuclei and goblet cells, 
similar as in colonic adenomas [2, 28]. Immunohistochemically, 
the tumor cells typically express MUC(mucin)2, MUC5, and cau-
dal-type homeobox 2 (CDX2) [28, 29].
The pancreatobiliary type also typically involves the MD in the 
pancreatic head but produces comparably little mucin. It is charac-
terized by complex arborizing papillae lined by cuboidal cells that 
resemble the pancreatic and biliary duct cells [6]. Immunohisto-
chemically, the tumor cells are positive for MUC1 and MUC5 [30].
The gastric type is typically found in BD-IPMNs [28, 29]. These 
cells resemble gastric foveolar cells, form pyloric gland-like struc-
tures at the base of the papillae, and express MUC5 and MUC6 [4, 
28, 30].
Oncocytic-type IPMNs typically display complex, arborizing 
papillae with delicate stroma, lined by two or more layers of onco-
cytic cells [6]. Immunohistochemically, the tumor cells reveal posi-
tivity for MUC1 and MUC6 [6].
Irrespective of the macroscopic or histological subtypes, IPMNs 
are classified according to their degree of dysplasia (fig. 2) [6]. Ac-
cording to the current WHO classification of tumors [6], the grade 
of dysplasia is determined as low-grade (formerly referred to as ad-
enoma), intermediate-grade (borderline type), or high-grade (car-
cinoma in situ) in noninvasive IPMN. About 30% of resected 
IPMNs reveal an association with uni- or multifocal invasive carci-
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nomas [6]. In 59–75% of these cases, the invasive tumor compo-
nent resembles conventional ductal adenocarcinomas, while 24–
41% display the phenotype of a mucinous (colloid) carcinoma 
[31–34]. The phenotype of the invasive tumor component depends 
on the IPMN subtype: thus, IPMNs of the pancreatobiliary, gastric, 
or oncycytic type result in an invasive phenotype resembling pan-
creatic ductal adenocarcinomas, while intestinal IPMNs may pro-
gress into invasive cancer either showing a colloid phenotype or 
resembling ductal adenocarcinoma [6].
Of note, IPMNs are frequently heterogeneous regarding the de-
gree of dysplasia. Therefore, a histological workup of the entire le-
sion may be necessary to exclude malignancy.
The prognosis of IPMN is mainly determined by the presence 
and extent of an invasive carcinoma. In matched-pair analyses, 
IPMNs showed a significantly better survival than conventional 
pancreatic ductal adenocarcinomas, with 5-year survival rates of 
38–47 versus 16% and median survival times of 32–47 versus 17–19 
months, respectively [31, 34, 35]. IPMN-associated carcinomas with 
colloid or oncocytic phenotpyes showed a significantly better prog-
nosis than IPMN-associated or conventional ductal adenocarcino-
mas. However, while this survival benefit was prominent in early 
tumor stages, it was lost in more progressed tumors with nodal me-
tastases. This finding was explained by the observation that colloid 
carcinomas were more frequently resected at lower T stages and 
showed less nymph node metastases, highly differentiated tumor 
grades, as well as less neural and vessel invasion [31, 34, 35].
Clinical Symptoms and Risk Factors
Symptoms rarely appear in low-grade IPMNs and often arise in 
advanced stages of IPMN only when malignant transformation has 
already occurred [2]. The symptoms that these patients present 
with may include abdominal pain, jaundice, weight loss, or episodic 
pancreatitis-like symptoms [2]. Furthermore, the development of 
diabetes early in the course of disease is a large clinical risk factor 
for malignancy and has been demonstrated in multiple studies. In 
2012, the revised Sendai criteria proposed a classification including 
clinical and radiological findings to predict malignancies. These 
guidelines suggested two categories called ‘high-risk stigmata’ (ob-
structive jaundice, enhanced solid components, dilatation of main 
pancreatic duct greater than 10 mm) and ‘worrisome features’ (his-
tory of pancreatitis, maximal cyst diameter greater than 30 mm, 
thickened and enhanced cyst wall, MPD diameter 5–9 mm, non-
enhanced mural nodules, abrupt change of caliber of the MPD with 
distal pancreatic atrophy and lymphadenopathy). Unlike the pres-
ence of high-risk stigmata, the presence of worrisome features does 
not necessarily lead to the recommendation of surgical intervention 
[2]. The Fukuoka guidelines (revised Sendai guidelines) do not in-
dicate whether the number of factors in either category correlates 
with the likelihood of malignancy. A recent study stratified patients 
with BD-IPMN into three groups with regard to high-risk stigmata 
or worrisome features. The presence of one high-risk stigmata justi-
fied pancreatic resection, while in contrast there was no significant 
correlation between the number of worrisome features and the 
grade of malignancy [36].
Imaging Features of IPMNs
It is commonly the case that patients with IPMN have no symp-
toms and that the neoplasm is detected incidentally when imaging 
studies are performed for unrelated indications [2, 5]. As such, 
there is often a delay in diagnosis due to the insidious nature of this 
entity [37, 38]. 
As IPMNs are usually incidental radiological findings it is im-
portant to determine the risk of malignancy and subsequent man-
agement; however, this is a difficult task. There has been much re-
search into the predictors of malignancy of IPMNs, including two 
revisions of the international consensus guidelines [2, 8].
The imaging predictors of malignancy in IPMNs can be compli-
cated; however, they can be subdivided into the following head-
ings: ‘type’, ‘size’, ‘focal cyst findings’, ‘MPD dilation’, and ‘associ-
ated pancreatic findings’. All of these can be obtained with conven-
tional imaging techniques. It is important to note that all of these 
findings as well as the patients’ history have to be taken into con-
sideration when assessing the risk of malignancy. 
Type
As previously described, IPMNs are cystic lesions that arise 
from the MPD (MD-IPMNs), its BDs (BD-IPMNs), or both 
(mixed-type IPMN). MD-IPMNs can be differentiated from BD-
IPMNs by their location. Dilation of the MD ˰10 mm (or 5–6 mm 
as a suspicious/worrisome feature) without an evident reason leads 
to the differential diagnosis of MD-IPMN [4, 7, 39]. IPMNs arising 
from the MPD have a higher risk of malignancy, and this finding 
indicates surgical resection. BD-IPMNs are recognized as cystic di-
lations of pancreatic BDs, usually showing a grape-like appearance 
in magnetic resonance cholangiopancreatography (MRCP) with 
the stalk of the grape representing the small, non-dilated connec-
tion duct between the BD and the MPD (fig. 3). These BD dilations 
can be more tubular, too. Mixed-type IPMNs are diagnosed when 
both features of BD- and MD-IPMNs are present. In general, the 
connection to the pancreatic duct can be best visualized by MRCP 
Fig. 3. BD-IPMN – 
note the connection of 
the lesion via a branch 
duct to the main duct; 
the arrowhead points 
at the BD from which 
the IPMN arises.
Cyst Features and Risk of Malignancy in IPMN of 
the Pancreas
Viszeralmedizin 2015;31:31–37 35
with a sensitivity of 91.4 to 100% and a specificity of 89.7% [40]. If 
a connection of the duct to the cystic lesion can be visualized, the 
only remaining differential diagnosis is a pancreatic pseudocyst or 
a BD-IPMN. Endosonographic ultrasound (EUS) might be able to 
suggest a duct connection to the cystic lesion; however, sensitivity 
and specificity are lower when compared to magnetic resonance 
pancreatography or endoscopic retrograde pancreatography.
The study by Manfredi et al. [3] showed that the 5-year survival 
rate is not statistically significant between MD-IPMNs and mixed-
type IPMNs; thus, they should be more diligently approached with 
a lower threshold for resection. 
Size
One of the most controversial aspects of BD-IPMNs is the topic 
of cyst size. It was initially thought that all lesions ˰30 mm in di-
ameter should be resected due to their perceived high malignancy 
rate. However, size alone is not a significant predictor of malig-
nancy in MD-, BD-, or mixed-type IPMNs [41]. A study by Fritz et 
al. [27] has shown that IPMNs under 10 mm in size may still confer 
malignancy. Although size is an unreliable predictor of malig-
nancy, it should be emphasized that especially those patients with 
larger lesions should be monitored, and the Fukuoka criteria have 
kept a size of 30 mm as a worrisome feature. 
Focal Cyst Findings
Some of the strongest predictors of malignancy in all types of 
IPMNs involve focal cyst findings. In studies using magnetic reso-
nance imaging to look at the characteristics of the duct in relation 
to all IPMNs, it was found that mural nodules along the walls of 
the pancreatic ducts and duct wall enhancement with increased 
cyst wall thickness are predictors of malignancy (fig. 4A). In a sum-
mary statistic comprising 539 patients with BD-IPMN, 165 pa-
tients displayed a cyst greater than 3 cm, and 54 of them harbored 
nodules. 83.3% of those patients were either found to suffer from 
invasive cancer or had high-grade dysplasia. In comparison, only 
40 out of 367 patients had nodules in cysts smaller than 3 cm. 
However, 58% of those were found to be malignant on resection, 
proving the concept that mural nodules are the strongest predic-
tors of malignancy in BD-IPMNs [42]. Recent studies suggest that 
an increasing height of nodules predicts the specificity and accu-
racy of malignancy with a cut-off of 10 mm [43, 44]. Recent studies 
comparing imaging modalities showed that EUS is superior in the 
detection of worrisome features in BD-IPMNs (fig.  4B and C); 
therefore, it was suggested that follow-up should be performed by 
EUS [42]. Contrast-enhanced endosonography can aid to the dif-
ferentiation between mucus and mural nodules and helps in pre-
dicting malignant transformation [45]. If it comes to the diagnosis 
of BD-IPMN, a major focus is put on FNA of cystic fluid as well as 
cytology from mural nodules and the cyst wall. The initial study by 
Brugge et al. [46] proposed a cut-off of 192 ng/ml for carcinoem-
bryonic antigen (CEA) in cyst fluid to confirm the diagnosis of a 
mucinous lesion. Meta-analyses studying the value of CEA in cyst 
fluid calculated a positive predictive value of 96% for CEA levels 
greater than 400 ng/ml and a negative predictive value of 98% for 
CEA levels below 5 ng/ml. Of note, neither does the level of CEA in 
cyst fluid correlate with malignancy nor does carbohydrate antigen 
(CA) 19-9 have any significant predictive value in the diagnosis of 
a mucinous lesion. Yoon et al. [47] recently correlated the level of 
CEA in cyst fluids to the histological subtypes of BD-IPMNs de-
scribed above. While gastric-type IPMNs were smaller in diameter 
and less likely to develop mural nodules or mass lesions, CEA lev-
els were with a median of 619 ng/ml highest in comparison to pan-
creatobiliary-type (270 ng/ml), intestinal-type (83 ng/ml), or onco-
cytic-type (5.1 ng/ml) IPMNs [47]. Kanda et al. [48] added a new 
dimension to the differential diagnosis of cystic pancreatic lesions. 
Fig. 4. A BD-IPMN – note the mural nodule associated with the cyst wall. 
B BD-IPMN on EUS – note the mural associated to the cyst wall with an ap-
proximate size of 10 mm (arrow). C The nodule was found to harbor high-
grade dysplasia on FNA (Papanicolaou staining × 600).
B
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By next-generation sequencing of DNA extracted from secretin-
stimulated pancreatic juice or cyst fluid aspirate, mutations at 
codon 202 of a small g-protein GNAS were detected. 64.1% of the 
patients with histologically proven IPMN displayed GNAS muta-
tions while neither SCN nor MCN, nor pseudocysts showed these 
mutations. If KRAS and GNAS mutations were studied, up to 96% 
of the patients harbored these mutations [39, 48–51]. Therefore, 
GNAS and KRAS mutations might represent the new armamen-
tarium for differential diagnosis of IPMNs. 
MPD Dilation
The diameter of the MPD is an important independent feature 
in determining a malignant risk. A dilation of ˰10 mm should be 
regarded as highly suspicious (fig. 5). Furthermore, those with an 
MPD of 5–9 mm in diameter are also dubbed as lesions with worri-
some features. However, a non-dilated pancreatic duct does not 
predict a benign lesion. 
Associated Findings
There are other radiological findings of the pancreas that also 
imply malignancy, including distal pancreatic atrophy with an 
abrupt change in MPD diameter. Furthermore, the association of 
local lymphadenopathy may also help in conferring malignancy. 
Non-Radiological Predictors of Malignancy 
The use of tumor markers is important in the determination of 
malignancy of all tumors. A study by Fritz et al. [27] has shown 
that CA 19-9 has proven to be an independent predictor of malig-
nancy and should be taken into account when determining malig-
nancy preoperatively. 
Conclusion
IPMNs are a distinct cystic neoplasm arising from the MPD or 
its branches. With an unknown etiology, associated with GNAS 
mutations and their ability to progress to malignant lesions, their 
presence poses a potential life-threatening risk to the patient. Cor-
rect preoperative diagnosis and risk stratification therefore need to 
be the pillars of clinical management [2, 4, 17, 52, 53]. Much of the 
difficulty comes from the inability to accurately distinguish malig-
nant lesions from their benign precursors. And even if all imaging 
modalities are employed, the accuracy of diagnosis is given with 
80%. Moreover, if patients with BD-IPMNs are resected for ‘worri-
some features’, malignancy is only detected in 30%, and the final 
diagnosis is given with MCN, SCN, or non-neoplastic cyst (con-
genital or pseudocysts) in 20%. Furthermore, the decision for re-
section remains quite challenging as many of the radiological char-
acteristics are controversial and contentious, even with the addi-
tion of pathologic markers. There is still a need for further studies 
looking into features associated with malignancy of these lesions, 
providing the clinicians in an elderly, multimorbid population 
with better tools to decide which lesions to resect and which to fol-
low up.
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Fig. 5. MD-IPMN – 
note the marked main 
duct dilation without 
visualization of a reason 
(no sudden break-off).
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